​

Bioventus (BVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BVS Stock Forecast

Bioventus (BVS) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $8.83, with a high of $12.00 and a low of $2.50. This represents a 12.92% increase from the last price of $7.82.

- $3 $6 $9 $12 $15 High: $12 Avg: $8.83 Low: $2.5 Last Closed Price: $7.82

BVS Stock Rating

Bioventus stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

BVS Price Target Upside V Benchmarks

TypeNameUpside
StockBioventus12.92%
SectorHealthcare Stocks 35.25%
IndustryMedical Device Stocks21.20%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$10.67
Last Closing Price$7.82$7.82$7.82
Upside/Downside--36.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-21--3
Mar, 25-21--3
Feb, 25-21--3
Jan, 25-21--3
Dec, 24-21-14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 01, 2024Caitlin CroninCanaccord Genuity$12.00$11.791.78%53.45%
Aug 07, 2024Chase KnickerbockerCraig-Hallum$12.00$8.2545.45%53.45%
May 07, 2024William PlovanicCanaccord Genuity$8.00$5.1256.25%2.30%
Mar 13, 2024Alex NowakCraig-Hallum$9.00$5.2970.13%15.09%
Nov 30, 2022Goldman Sachs$2.50$1.9130.89%-68.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024RBC CapitalOutperformupgrade
Oct 01, 2024Canaccord GenuityBuyBuyhold
Sep 27, 2024Craig-HallumBuyBuyhold
Aug 07, 2024Craig-HallumBuyBuyhold
May 07, 2024Canaccord GenuityBuyBuyhold
Dec 07, 2023Canaccord GenuityBuyupgrade
Nov 30, 2022Goldman SachsNeutralNeutralhold
Nov 22, 2022Craig-HallumHolddowngrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$0.29$0.16$-3.48$-2.49$-0.75--
Avg Forecast$0.86$0.90$0.26$-0.30$0.40$0.56$0.78
High Forecast$0.86$0.90$0.26$-0.29$0.42$0.59$1.13
Low Forecast$0.86$0.90$0.25$-0.31$0.39$0.55$0.43
Surprise %-66.28%-82.22%-1438.46%730.00%-287.50%--

Revenue Forecast

$300M $370M $440M $510M $580M $650M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$321.16M$430.90M$512.12M$512.35M$573.28M--
Avg Forecast$320.87M$430.39M$521.72M$500.90M$564.94M$570.79M$607.84M
High Forecast$321.72M$431.54M$528.07M$517.14M$583.25M$589.29M$607.92M
Low Forecast$319.56M$428.64M$510.79M$492.67M$555.66M$561.41M$607.76M
Surprise %0.09%0.12%-1.84%2.29%1.48%--

Net Income Forecast

$-250M $-180M $-110M $-40M $30M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$16.41M$9.59M$-213.39M$-156.23M$-49.13M--
Avg Forecast$53.88M$56.44M$16.13M$-19.03M$25.45M$35.76M$48.87M
High Forecast$54.06M$56.64M$16.39M$-18.43M$26.25M$36.88M$70.80M
Low Forecast$53.59M$56.14M$15.69M$-19.62M$24.65M$34.63M$26.93M
Surprise %-69.54%-83.02%-1422.80%721.18%-293.03%--

BVS Forecast FAQ

Is Bioventus stock a buy?

Bioventus stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bioventus is a favorable investment for most analysts.

What is Bioventus's price target?

Bioventus's price target, set by 5 Wall Street analysts, averages $8.83 over the next 12 months. The price target range spans from $2.5 at the low end to $12 at the high end, suggesting a potential 12.92% change from the previous closing price of $7.82.

How does Bioventus stock forecast compare to its benchmarks?

Bioventus's stock forecast shows a 12.92% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the medical device stocks industry (21.20%).

What is the breakdown of analyst ratings for Bioventus over the past three months?

  • April 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Bioventus’s EPS forecast?

Bioventus's average annual EPS forecast for its fiscal year ending in December 2025 is $0.56, marking a -174.67% decrease from the reported $-0.75 in 2024. Estimates for the following years are.

What is Bioventus’s revenue forecast?

Bioventus's average annual revenue forecast for its fiscal year ending in December 2025 is $570.79M, reflecting a -0.43% decrease from the reported $573.28M in 2024. The forecast for.

What is Bioventus’s net income forecast?

Bioventus's net income forecast for the fiscal year ending in December 2025 stands at $35.76M, representing a -172.78% decrease from the reported $-49.126M in 2024. Projections indicate .